VJOncology is committed to improving our service to you

ESMO WCGIC 2020 | NALIRIFOX as frontline therapy for PDAC

VJOncology is committed to improving our service to you

Zev Wainberg

Zev Wainberg, MD, of Ronald Reagan UCLA Medical Center, Los Angeles, CA, discusses primary analysis from a Phase I/II study investigating first-line liposomal irinotecan and 5-fluorouracil/leucovorin and oxaliplatin (NALIRIFOX) in newly diagnosed patients with pancreatic ductal adenocarcinoma (PDAC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter